A Set of Diagnostic Tests for Detection of Active Babesia duncani Infection 1

- Meenal Chand¹, Pratap Vydyam¹, Anasuya C. Pal¹, Jose Thekkiniath¹, Dounia Darif¹, Zeng 2
- Li¹, Jae-Yeon Choi¹, Ruben Magni², Alessandra Luchini², Laura Tonnetti³, Elizabeth J Horn⁴, 3
- Danielle M Tufts^{5,6} and Choukri Ben Mamoun^{1*} 4
- ¹Department of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, 5 New Haven, CT 06520. 6
- ²School University, 7 of Systems Biology, George Mason 4400 University Dr. Fairfax, VA 22030. 8
- ³Scientific Affairs, American Red Cross, Rockville, MD 20852. 9
- ⁴Lyme Disease Biobank, Portland, OR 97221. 10
- ⁵Department of Infectious Diseases and Microbiology, University of Pittsburgh School of 11 Public Health, 2119 Public Health, 130 DeSoto Street, Pittsburgh, PA 15261, 12
- ⁶ Department of Veterinary Tropical Diseases, University of Pretoria, South Africa. 13
- *Correspondence: choukri.benmamoun@yale.edu 14
- Keywords: Human babesiosis, Apicomplexan parasite, Babesia duncani, antigen capture, 15
- ELISA, Antibodies, Infectious disease, Tick-borne diseases 16
- Running Title: Diagnostic Tool for Active Babesia duncani Infection. 17
- 18

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 ABSTRACT

20 Human babesiosis is a rapidly emerging and potentially fatal tick-borne disease caused by 21 intraerythrocytic apicomplexan parasites of the Babesia genus. Among the various species of 22 Babesia that infect humans, B. duncani has been found to cause severe and life-threatening 23 infections. Detection of active B. duncani infection is critical for accurate diagnosis and 24 effective management of the disease. While molecular assays for the detection of B. duncani 25 infection in blood are available, a reliable strategy to detect biomarkers of active infection has not yet been developed. Here, we report the development of the first B. duncani antigen 26 27 capture assays that rely on the detection of two B. duncani-exported immunodominant antigens, BdV234 and BdV38. The assays were validated using blood samples from cultured 28 parasites in human erythrocytes and B. duncani-infected laboratory mice at different 29 parasitemia levels and following therapy. The assays display high specificity with no cross-30 reactivity with B. microti, B. divergens, Babesia MO1, or P. falciparum. The assay also 31 32 demonstrates high sensitivity, detecting as low as 115 infected erythrocytes/µl of blood. 33 Screening of 1,731 blood samples from diverse biorepositories, including previously identified Lyme and/or B. microti positive human samples and new specimens from field 34 35 mice, showed no evidence of B. duncani infection in these samples. The assays could be useful in diverse diagnostic scenarios, including point-of-care testing for early B. duncani 36 infection detection in patients, field tests for screening reservoir hosts, and high-throughput 37 screening such as blood collected for transfusion. 38

39 Short summary:

We developed two ELISA-based assays, BdACA38 and BdACA234, for detecting B. 40 duncani, a potentially fatal tick-borne parasite causing human babesiosis. The assays target 41 42 two immunodominant antigens, BdV234 and BdV38, demonstrating high specificity (no cross-reactivity with other Babesia species or Plasmodium falciparum) and sensitivity 43 (detecting as low as 115 infected erythrocytes/µl). The assays were validated using in vitro-44 cultured parasites and infected mice. Screening diverse blood samples showed no evidence of 45 B. duncani active infection among 1,731 human and field mice blood samples collected from 46 47 the north-eastern, midwestern, and western US. These assays offer potential in diverse diagnostic scenarios, including early patient detection, reservoir animal screening, and 48 transfusion-transmitted babesiosis prevention. 49

51 INTRODUCTION

In recent years, vector-borne infectious diseases have emerged as a significant global public 52 health concern (1). The expansion of the geographic range of the tick vectors has led to a 53 54 notable increase in tick-borne diseases (TBDs), which now account for more than 75% of all reported vector-borne diseases in the United States annually (2-4). Among these tick-borne 55 diseases is human babesiosis, an emerging infectious disease caused by intraerythrocytic 56 apicomplexan parasites of the Babesia genus (5). In 2011, the disease became a US national 57 58 notifiable condition in 18 states, which led to a significant increase in the number of reported 59 cases. A recent report by the US Centers for Disease Control and Prevention (CDC) documented a rapid surge in human babesiosis cases over the past decade, 16,456 clinical 60 61 cases were reported between 2011 and 2019 primarily in 37 states, with 98.2% of cases reported concentrated in 10 states (6). While ticks are the main vehicle of transmission of 62 *Babesia* parasites, blood transfusion remains a major concern despite screening efforts. 63

To date, eight species of *Babesia* have been identified as human pathogens and documented 64 to cause mild to severe babesiosis with some cases resulting in fatal outcomes (7). The 65 66 majority of clinical cases reported to the CDC are attributed to Babesia microti (8, 9), 67 whereas only a few cases of B. duncani babesiosis have been documented in the United States, primarily in Washington, Oregon, and California. However, it is crucial to 68 69 acknowledge that some of the B. microti cases might be attributed to B. duncani. This observation underscores the significance and justifies the necessity for a new and highly 70 71 sensitive diagnostic test capable of distinguishing between the two Babesia species. Indeed, 72 as per the CDC Babesiosis Surveillance Report (2011-2015) in the United States, three babesiosis cases were linked to B. duncani in Maryland and Connecticut (10) based on 73 serological criteria. This underscores the concern regarding the presence and potential threat 74

of *B. duncani* on the East Coast and validates the need for a new, highly sensitive diagnostic
test that is specific to *B. duncani*.

In confirmed cases of *B. duncani* babesiosis, the parasite was found to induce fulminant and
often fatal infections in both immunocompetent and immunocompromised individuals (1114). Available data suggest that the hard tick *Dermacentor albopictus* serves as the vector for *B. duncani* (13).

81 To date, the true incidence of *B. duncani* babesiosis remains unknown. Accurate determination of the true prevalence of B. duncani babesiosis is challenging due to the 82 83 absence of specific and reliable diagnostic tests that can determine active infection. Over the diagnostic techniques including microscopy, serological tests like 84 years, various immunofluorescence assay (IFA), immunoblot and enzyme-linked immunosorbent assay 85 (ELISA), and nucleic acid-based tests such as nested PCR, reverse transcription-polymerase 86 87 chain reaction (RT-PCR), and transcription-mediated amplification (TMA), have been employed to detect Babesia infections. Morphologically, B. duncani-infected red blood cells 88 89 (RBCs) are indistinguishable from those infected with *B. microti* or other *Babesia* species and bear resemblance to the ring-stage forms of *Plasmodium falciparum*, the causative agent of 90 severe human malaria. Therefore, microscopy cannot be reliably used to diagnose *B. duncani* 91 active infection in a blood sample. With the exception of cases confirmed by both 92 93 microscopy and PCR (14-19), most unverified cases attributed to this parasite have relied on 94 serological assays, which cannot reliably distinguish between past and active infections. A 2018 publication by Scott and Scott summarized reports by physicians and naturopathic 95 physicians of 1119 cases of B. duncani between 2011 and 2017 in Canada, with most cases 96 97 occurring in the Pacific Coast region (20). However, no positive blood smears or details about the sensitivity or specificity of the serological and molecular assays used were 98 described in that report. Furthermore, no appropriate controls were included in these studies. 99

100 Therefore, these claims warrant further validation, which could be facilitated by sharing blood samples with established biorepositories and large-scale blood screening in different 101 geographic areas in the US. Nucleic acid-based detection techniques are indeed more specific 102 103 and sensitive and have been effective in identifying positive B. microti blood samples. Nevertheless, in some instances, these techniques have been shown to detect residual parasite 104 DNA or RNA even after the parasite has been eliminated (21, 22). Recent studies using 105 106 microscopic examination of blood samples from B. microti-infected animals treated with drugs that cleared the infection demonstrated the presence of residual DNA after treatment 107 108 with antibabesial drugs (22). Studies using *B. microti*-infected blood revealed that antigen detection assays, which rely on the detection of highly abundant and often immunodominant 109 secreted antigens of the parasite, exhibit a stronger correlation with active B. microti infection 110 compared to Nuclic Acid-detection assays (23). Therefore, efforts to develop similar assays 111 for the detection of active infections by other Babesia species could be an invaluable resource 112 to estimate the true incidence of babesiosis caused by each of the Babesia species that cause 113 infection in humans. This is particularly important in light of the rapid environmental changes 114 impacting the transmission of these diseases and other TBDs (24, 25). 115

A significant breakthrough in the field of *B. duncani* biology emerged with the establishment of the first continuous *in vitro* culture system of *B. duncani* in human erythrocytes (26-28). Furthermore, the recent sequencing and annotation of the parasite's genome (29) made it possible to apply a multi-faceted approach that incorporates genomic, transcriptomic, and proteomic analyses to identify unique and species-specific proteins that are exported by the parasite from infected RBCs into the host plasma.

In this study, we report the discovery of two highly reliable biomarkers for active *B*. *duncani* infection. *Babesia duncani*-specific antigen capture assays (BdACAs) that detect these antigens were developed and exhibit high sensitivity, are capable of detecting as low as

- 125 115 parasites/µl of blood and can distinguish active infections from past exposures, and can
- 126 distinguish between *B. microti* and *B. duncani* to provide accurate species infections,
- important for public health.

128 MATERIALS AND METHODS

Ethics statement-- All animal experiments described in this study followed the Yale University institution guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committee at Yale University (protocol number 2023-07689).

Babesia duncani infection in mice-- C3H/HeJ or SCID mice (C.B-17/IcrHsd-Prkdcscid) 5-6 133 week, female mice from Jackson laboratories were infected by injecting 1×10^6 or $1 \times 10^7 B$. 134 duncani WA-1 strain or B. microti LabS1 strain, respectively by infected erythrocytes 135 intravenously (IV) from the stock mouse. Blood samples were collected at different time 136 points by a retro-orbital bleed or cardiac puncture, and parasitemia was monitored by light 137 microscopy of Giemsa-stained blood smears. Where indicated, plasma or serum was 138 separated from whole blood by centrifugation at 6000g for 10 min, and packed mouse RBC 139 (mRBC) was lysed with 1% saponin. Hemolysate and parasite pellets were collected after 140 centrifugation at 9300g for 10 min at 4°C. 141

Babesia duncani in vitro culture-- Babesia duncani WA-1 parasites were cultured
continuously in human erythrocytes in DMEM-F12 media (28), as described previously (26).
(Included in Supplementary methods).

Isolation of extracellular vesicles from plasma, culture supernatant, and hemolysate -Extracellular membrane vesicles containing protein cargo released from the parasite were
isolated from supernatant/plasma and hemolysate of *B. duncani in vitro* and *in vivo* culture by
EXO Quick ULTRA EV isolation kit (EQULTRA-20A-1) following the user manual. Where
indicated, vesicles were also isolated by the ultracentrifugation method, as mentioned
previously (30). Briefly, 1.5 ml of human RBC (hRBC) and mRBC samples (uninfected and *B. duncani* infected plasma/serum or supernatant and hemolysate) were sequentially

centrifuged at 500g for 30 min, followed by 16,000g for 45 min. These samples were then centrifuged at 120,000g for 14h at 4°C using a Sorvall MTX 150 micro-ultracentrifuge with an S52-ST swinging bucket rotor (Thermo Fisher) and ultracentrifuge pellet (Up/UHp) and ultracentrifugation supernatant (Us/UHs) fractions were collected (31).

Cloning, expression, and purification of recombinant proteins-- Plasmid DNA constructs
 for BdV234 and BdV38 were synthesized by GenScript, Inc., NJ. Details description of
 protein expression and purification provided in the supplementary methods.

Immunodetection of BdV234 and BdV38-- Polyclonal antibodies raised in rabbits 159 (Cocalico Biologicals, Inc., PA) against the indicated B. duncani proteins were purified and 160 used for the immunodetection analysis as described in detail (32). Briefly, supernatant (S), 161 162 hemolysate (H), and parasite pellet (P) fractions collected either from B. duncani in vitro 163 culture in hRBC (18% parasitemia) or B. duncani infected (24% parasitemia) or uninfected mRBCs were mixed with 4X Laemmli sample buffer (3:1 ratio), boiled at 80°C for 5 min and 164 165 separated on 4-20% Mini-protean gels (Bio-Rad, P4568093). The gels were then transferred onto nitrocellulose membranes (Bio-Rad, 1620115), probed with anti-BdV234 and BdV38 166 primary antibodies (1:250 dilution) and goat-anti-rabbit horseradish peroxidase (HRP)-167 conjugated IgG Ab (1: 5000 dilution, (Thermo Fisher, 31466). Blots were developed by 168 Super signalTM West Pico PLUS chemiluminescent substrate (Thermo Fisher, 34577) and 169 170 imaged using the LI-COR Odyssey-Fc imaging system.

Immunofluorescence assay (IFA)-- Immunofluorescence assay was performed as reported
 previously (30, 32) and described briefly in the supplementary methods.

BdACA using *B. duncani in vitro* culture supernatant and hemolysate fractions— *Babesia duncani* antigen capture sandwich ELISAs were performed as described earlier (22,
with few modifications. Briefly, 96-well plates were coated with 5µg/ml of capture Abs

(BdV234 and BdV38) and incubated for 2h at room temperature, followed by blocking with 176 5% BSA in PBST (0.05% Tween-20) at 37°C for 1h. Plates were then incubated overnight at 177 4°C with either (1) BdV38 and BdV234 recombinant protein (100 ng/well), (2) a 1 in 10 178 dilution of *B. duncani in vitro* culture supernatant, hemolysate, and whole blood, or (3) 179 plasma/serum (heat-inactivated for 30 min at 56°C), hemolysate and whole blood from 180 uninfected or *B. duncani* infected C3H/HeJ mice. Whole blood samples from American Red 181 182 Cross (ARC), Lyme Disease Biobank (LDB), and field-derived mouse samples were incubated similarly. The plates were then washed four times with PBST, and 5 µg/ml 183 184 biotinylated detection Ab (BdV234 and BdV38) were added and incubated at room temperature for 2h. Following this, plates were washed four times with PBST and incubated 185 with HRP conjugated streptavidin antibody in 1:5000 dilution at room temperature for 1h, 186 followed by washing and incubation with 50 µl 3,3',5,5' tetramethylbenzidine (TMB) 187 substrate for 7 min in the dark. The reaction was stopped by adding 50 µl of 0.1N HCl, and 188 the Optical Density at 450 nm was measured using a BioTek Synergy Mx plate reader. 189

Detection of BdV234 and BdV38 antigens in hemolysate from drug-treated B. duncani 190 in vitro culture or infected mouse blood-- In vitro B. duncani culture with an initial 191 192 parasitemia of 1% (cultured in 5% hematocrit with DMEMF-12 containing hRBCs) was exposed to tafenoquine (SML0396, Sigma Aldrich) at 1x IC₅₀ (3 μ M) and 2x IC₅₀ (6 μ M) 193 194 concentrations for three generations. Both untreated and tafenoquine treated parasite cultures were collected at specified time points (0, 3, 6, 12, 24, 36, 48, 60, and 72 hours post 195 treatment), lysed with 1% saponin, and the resulting hemolysates were used for ELISA. 196 Untreated infected and uninfected hRBCs were included as controls. Similarly, hemolysates 197 were prepared from blood from 12 C3H/HeJ (3 male, 3 female) mice infected with a high 198 dose of *B. duncani* (10⁶ parasites) and used in ELISA to detect BdV234 and BdV38. Six of 199 these mice were treated with tafenoquine for 5 days (DPI 3-7), and the remaining six were 200

treated with vehicles (PEG400). Vehicle-treated and uninfected mice hemolysates were usedas controls.

Genomic DNA extraction and Real-Time PCR-- To further confirm the presence or 203 absence of *B. duncani* DNA in infected blood, qPCR analyses were conducted as previously 204 reported (33). Briefly, blood from B. duncani in-vitro culture and B. duncani infected mouse 205 at various parasitemia levels were collected at specific time points post-infection, followed by 206 207 gDNA isolation by the DNeasy Blood and Tissue kit (Qiagen, 69504). The isolated genomic DNA were used to amplify the B. duncani internal transcribed spacer (ITS) sequence in its 208 209 nuclear rRNA (18s-rRNA) by using BdITS1-F 5'-GCTTCCTAACCCGAGACCAA-3' and BdITS1-R 5'-CACTGGCGGGGTGAAAAGTA-3' primers (34). The reaction mixture 210 contained 1× advanced universal SYBR green super mix (1725270; Bio-Rad), 1 µl of each 211 primer (10 μ M), and 2 μ l of template DNA. 212

Collection of biological samples used for screening *B. duncani* antigen/infection-- Two 213 hundred human whole blood samples were obtained from the American Red Cross (ARC), of 214 which 100 samples were positive for *B. microti* infection as detected by transcriptionally 215 mediated amplification (TMA) positive and the remaining 100 samples were TMA negative 216 for B. microti, the samples were collected in areas endemic for B. microti. (Connecticut, 217 Delaware, Massachusetts, Maryland, Maine, Minnesota, New Hampshire, New Jersey, New 218 219 York, Pennsylvania, Virginia, Vermont). Additionally, 770 whole blood samples were obtained from the Lyme Disease Biobank (LDB) with 317 samples enrolled with signs and 220 symptoms of early Lyme disease and 282 controls as previously described (35) and were 221 collected from East Hampton, Martha's Vineyard, and Wisconsin (2014-2020). Similarly 171 222 samples were collected from the west coast (California), including 11 enrolled with early 223 Lyme disease, 10 controls, and 150 with peresistent Lyme symptoms. Whole blood samples 224 were also obtained from 761 white-footed mice (Peromyscus leucopus), a prominent 225

- reservoir host of *B. microti*, (unscreened) that were collected from western Pennsylvania,
- 227 USA, and used in this study.

228 **RESULTS**

Identification of B. duncani secreted antigens. The genome of B. duncani has been 229 extensively studied and characterized. Its annotation identified 4222 proteins, of which 479 230 are predicted to be members of the parasite's secretome (29). To identify proteins exported 231 by the parasite into the host red blood cell and/or host environment, we used a Nanotrap-232 233 based proteomics approach (36, 37) on hemolysate (H) and secreted (S) fractions collected from a culture of *B. duncani*-infected human erythrocytes as shown in Fig. 1A. Mass 234 spectrometry analysis identified 27 proteins in the S fraction (Table 1) and 39 proteins in the 235 H fraction. Of these exported proteins, BdV234 and BdV38 were selected based on their 236 peptide abundance, high expression levels of their encoding genes as determined by RNAseq, 237 and predicted antigenicity profiles (Table 1). The genes encoding these two proteins were 238 cloned into the pGEX 6p-1 and pET21a (+) expression vectors, respectively, and the encoded 239 recombinant proteins were expressed in E. coli, purified on glutathione Sepharose high-240 performance (BdV234) and Ni-NTA agarose (BdV38) affinity columns and used to generate 241 specific polyclonal antibodies in rabbits. The antibodies were then affinity-purified and 242 evaluated for their specificity using recombinant proteins as well as total extracts from a 243 culture of *B. duncani*-infected erythrocytes. The resulting affinity-purified anti-BdV234 and 244 anti-BdV38 antibodies were used to detect the expression and cellular distribution of the 245 246 native proteins in the supernatant (S), hemolysate (H), or pellet (P) fractions from cultures of B. duncani-infected human erythrocytes and control uninfected human erythrocytes (Fig. 247 1B). Consistent with the export of these proteins, immunoblot analyses identified the native 248 BdV234 and BdV38 in all three fractions while no signal could be detected in the fractions 249 isolated from the uninfected erythrocytes (Fig. 1B). We then assessed the cellular distribution 250 of the same antigens in mice infected with B. duncani. Interestingly, whereas the antigens 251 could be readily detected in the H and P fractions prepared from mouse blood collected from 252

B. duncani-infected C3H/HeJ mice, the signal from the plasma (Pl) fraction was very weak, likely the result of dilution in the large volume of plasma collected from infected animals (**Fig. 1B**). Additionally no signal could be detected from the Pl, H, or P fractions prepared from blood collected from uninfected mice, further confirming the specificity of the antibodies raised against these proteins (**Fig. 1B**).

258

Evidence of vesicular-mediated secretion of BdV234 and BdV38 from B. duncani-259 260 infected erythrocytes. Recent studies in *B. microti* and *B. divergens* have demonstrated that several proteins of these parasites' are actively exported by using vesicular-mediated export 261 mechanisms (30, 38). To assess the mode of export of BdV234 and BdV38, the culture S and 262 H fractions of *B. duncani*-infected human erythrocytes, as well as the Pl and H fractions of *B.* 263 264 duncani-infected mice were subjected to ultracentrifugation at 120,000 x g for 14h at 4°C to separate the soluble (Us/UHs) and vesicle-associated membrane (Up/UHp) fractions. These 265 266 resulting fractions were then analyzed by immunoblotting using anti-BdV234 and anti-BdV38 antibodies to assess the presence or absence of the antigens. As shown in Fig. 1C, the 267 proteins were primarily found associated with the Up/UHp fractions in both human and 268 mouse infected samples (Fig. S1-A), indicating that once exported from the infected 269 erythrocytes, these antigens are associated with vesicles. This association was further 270 271 validated using the ExoQuick[®] vesicle isolation system, which was used to separate the supernatant fraction (Es/EHs) from the vesicle-rich pellet fraction (Ev/EHv) on plasma, 272 supernatant, and hemolysate fractions collected from uninfected or B. duncani-infected blood 273 (Fig. S1-B). As shown in Fig. 1D, both antigens were detected in the vesicle fractions (E_V or 274 HE_V) from the S, H, and Pl fractions obtained from B. duncani-infected human and mouse 275 RBCs, respectively. As a control, no signal could be detected in similar fractions prepared 276 from blood collected from uninfected human erythrocytes in vitro or uninfected C3H/HeJ 277

mice (Fig. 1D). Together these data demonstrate that BdV234 and BdV38 are exported by *B*.
 duncani-infected erythrocytes through a vesicular-mediated mechanism.

280

Cellular localization of selected B. duncani secreted proteins. In order to investigate the 281 localization and cellular distribution of BdV234 and BdV38 secretory proteins in B. duncani, 282 immunofluorescence assays (IFA) were conducted on uninfected or B. duncani-infected 283 human erythrocytes by using affinity-purified BdV234 and BdV38 antibodies from rabbit 284 sera. Anti-rabbit Alexafluor-488 was used for the detection of BdV234 and BdV38, and α-285 Band III antibody was used as a membrane marker for human RBCs. Interestingly, BdV234 286 was not only found to be localized inside the parasites but was also found in the host 287 288 erythrocytes displaying punctate vesicular staining (Fig. 2), which indicating that this GPI-289 anchored protein is secreted by the parasite into the host cytosol. On the other hand, BdV38 was found to be localized primarily within the parasites. The rabbit pre-immune sera served 290 291 as a control in our IFA, and no localization signal with BdV234 and BdV38 was observed other than the nucleus and RBC membrane (Fig. 2). 292

293

Development of *B. duncani* antigen capture Assays BdACAs. The discovery that BdV234 294 and BdV38 could be readily detected in the hemolysate and environment of B. duncani-295 296 infected erythrocytes led us to investigate the use of these two proteins as biomarkers of an active B. duncani infection. We used the anti-BdV234 and anti-BdV38 antibodies to design 297 an antigen capture sandwich ELISA assay (BdACA) to detect the exported proteins in B. 298 duncani-infected blood (Fig. 3A). The BdACA assays, one for each antigen, were initially 299 optimized by employing two-fold serial dilutions of recombinant BdV234 and BdV38 300 301 proteins to generate a standard curve. The ELISA data was graphed with optical density

against known antigen concentrations to obtaining sigmoidal curves (Fig. 3B). To further 302 validate the assays for native proteins at the cellular level, an *in vitro* culture of *B. duncani*-303 infected human erythrocytes at 18% parasitemia with 5% hematocrit was prepared, and the 304 supernatant and hemolysate fractions were collected, subjected to two-fold serial dilutions, 305 and used to detect the exported antigens. From our findings, both BdV234 and BdV38 306 effectively identified the presence of total parasite proteins that were secreted into the culture 307 308 supernatant and established a positive correlation with the percentage of parasitemia counted by microscopy (Fig. 3C). In addition, when the assays were conducted on the culture 309 310 hemolysate samples, we observed a comparable correlation accompanied by a marginal rise in the absorbance values (**Fig. 3D**). In both assay conditions, we observed nearly undetectable 311 levels of the proteins when using the supernatant and hemolysates from cultures of uninfected 312 human RBCs. We extended the BdACA validation into the established in vivo mouse model, 313 utilizing serum and plasma from *B. duncani*-infected mice (with ~24% parasitemia) (Fig. 3E), 314 along with the H fractions (Fig. 3F). We observed robust detection of the parasite antigens 315 when probing the mouse hemolysate fractions with both antibodies, while the levels were 316 merely undetectable in the serum or plasma fractions (Fig. 3E). As expected, there was no 317 detection in the serum, plasma, or hemolysate fractions from uninfected mice. 318

319

High sensitivity of BdACAs for detection of *B. duncani* infection. The sensitivity of the BdACAs was assessed using a culture of *B. duncani* at ~9 x 10^{6} *B. duncani*-iRBCs per ml, which was subsequently subjected to two-fold dilutions and allowed to proliferate for 24h in culture. For the comparison of BdACA with qPCR, we isolated the genomic DNA from the same samples and used it for PCR detection of the *B. duncani* 18s rRNA (**Fig. 4A**). The H fractions from the same cultures were further used to evaluate the sensitivity of the BdACAs. The Bd38ACA could detect as low as 1 x 10^{3} iRBCs, while Bd234ACA could detect as low

as 2×10^3 iRBCs (Fig. 4B-C). No reactivity was observed in uninfected human RBCs, as 327 expected. The limit of blank (LOB) marked the threshold above which all values were 328 considered positive, while the limit of detection (LOD) for Bd38ACA and Bd234ACA was 329 330 determined to be 3 x of LOB ($OD_{450}=0.3$). The sensitivity of BdACA was also assessed to establish the minimum detectable level of parasitemia. A 1 ml of B. duncani in vitro culture 331 with an initial parasitemia of 0.5% (5% hematocrit) was allowed to grow over time, and 332 parasitemia was monitored. After isolating the hemolysate (1 ml), genomic DNA extraction 333 was performed to facilitate quantitative polymerase chain reaction (qPCR) analysis (Fig. 4D). 334 335 The BdACA assay employed 5 microliters per well alongside the previously mentioned hemolysate volume. Our findings demonstrated that the BdACA method effectively 336 identified parasitemia levels as low as 0.5%, consistent with the expected sensitivity. 337 Additionally, as the secretion of antigens increased over time, our assays could detect more 338 secreted antigens (Fig. 4E-F). Similarly, to validate the sensitivity of the assay in vivo 339 samples, blood was collected from day post-infection (dpi) 0-7 from C3H/HeJ mice. 340 Genomic DNA isolated from parasites at different time points was used in qPCR using B. 341 duncani 18s rRNA forward and reverse primers that detected parasites as early as 0-dpi (Fig. 342 4G), while Bd38ACA and Bd234ACA could detect the antigens as early as 2 and 3 dpi, 343 respectively (Fig. 4H-I). 344

345

BdV38 and BdV234 as biomarkers for evaluating antibabesial treatment efficacy. An
ideal biomarker of active *Babesia* infection is one whose levels show an excellent positive
correlation with parasitemia levels and does not remain in the blood following clearance of
infection due to drug treatment. To assess whether BdV38 and BdV234 meet these criteria,
BdACAs were conducted on *in vitro B. duncani* cultures under both untreated and drug-

treated conditions. Parasite cultures with 1 % parasitemia were initially inoculated and 351 collected at 12h intervals over a 72h period (three parasite erythrocytic lifecycles) following 352 treatment with either vehicle control (DMSO) or tafenoquine (TQ) at 3 µM (1x IC₅₀) and 6 353 μ M (2x IC₅₀). The samples were assessed for parasitemia detection in both conditions 354 through microscopic analysis of Giemsa-stained blood smears. Observations from Giemsa-355 stained blood smears at stipulated time intervals of post-inoculation displayed continuous 356 parasite growth until 72h (Fig. 5A). The decline in % parasitemia over time and the 357 inhibitory impact of 1x and 2x IC₅₀ of tafenoquine were evident, detecting parasitemia as low 358 359 as 0.05% and 0.1% at 48h compared to the untreated (UT) parasites, which reached approximately 10% after 72h post-inoculation (Fig. 5A). The detection of BdV38 from the 360 total parasite lysate positively correlated with the viability of the parasite over time in 361 untreated (UT) samples (Fig. 5B). In contrast, the curve declined over time and reached a 362 plateau after 48h with tafenoquine treatment (1x or 2x) (Fig. 5B). For post-drug treatment, as 363 tafenoquine cleared the parasites from the culture, the total absorbance showed nearly no 364 difference compared to the uninfected RBC lysate. Upon qPCR analysis of the same samples 365 to assess parasite detection, the presence of B. duncani DNA was indicated in both the 366 untreated and treated conditions at stipulated time intervals. However, a clear difference was 367 observed between the uninfected and infected samples (Fig. 5C). Similarly, we used whole 368 blood samples from uninfected and *B. duncani*-infected (10^6) mice that were treated with 369 370 tafenoquine (TQ) or vehicle. Blood samples were tested to assess parasite growth by microscopy (Fig. 5D), and BdV38ACA was used to detect BdV38 secretion that declined 371 after 7 dpi once the parasites were cleared by the drug treatment (Fig. 5E). qPCR results 372 373 suggested DNA remained in circulation even after the parasites were cleared (Fig. 5F). Thus, the Bd38ACA assay reliably detected only active infections. Similarly we tested these in vito 374

and *in vivo* samples with anti-BdV234 antibody and found the similar results as with BdV38
(Fig. S3).

377

Bd38ACA and Bd234ACA are highly specific assays for B. duncani detection. To assess 378 the specificity of the BdACA assays, we tested blood samples infected with other *Babesia* 379 species and similar apicomplexan parasites, such as *P. falciparum* from *in vitro* culture as 380 well as from animal hosts. We also compared the sensitivity of BdACA from uninfected and 381 *B. microti* (10⁶) infected mouse blood. Uninfected and *B. duncani*-infected mouse blood was 382 used as a control. Our in vivo results indicated that Bd38ACA (Fig. 6A) and Bd234ACA 383 (Fig. 6C) are highly specific for *B. duncani*-secreted proteins compared to *B. microti*. 384 385 Similarly, the assays were conducted on *in vitro* blood samples from different cultures of B. 386 divergens (Rouen87 strain), Babesia MO1, or P. falciparum (3D7 strain), each with 10% parasitemia grown in human erythrocytes. Our result indicated that Bd38ACA (Fig. 6B) and 387 Bd234ACA (Fig. 6D) only detect the respective proteins secreted by B. duncani, and no 388 signal above the lower limit detection of OD 0.3 could be detected in these samples. 389

390

Blood screening using Bd38ACA. To evaluate the effectiveness of BdACA as screening 391 tools for detecting active B. duncani infections, we employed the Bd38ACA assay to screen 392 1,731 whole blood specimens from diverse locations across the US. These encompassed 200 393 human whole blood samples (100 B. microti-positive and 100 B. microti-negative) from the 394 American Red Cross (ARC); 770 human whole blood samples from the Lyme Disease 395 Biobank (LDB), previously screened for Lyme disease and *B. microti*; and 761 whole blood 396 samples from white-footed mice collected from Western Pennsylvania (Fig. 7A). In this 397 study, the lower limit of detection (LOD; $OD_{450} = 0.3$) was defined as thrice of the LOB 398

(lower limit of blank), which corresponds to a *B. duncani* parasitemia of 0.3% (Fig. 7B). All 399 1,731 samples, analyzed in this study, showed OD_{450} values below 0.6, which when 400 401 compared to the standard curve for *B. duncani* parasitemia levels corresponds to parasitemia 402 levels below 0.55% (Fig. 7A). Of these 1731 samples, 8 had OD₄₅₀ values between 0.31 and 0.59. Among the 761 white-footed mouse samples, 756 showed signals below the LOD and 5 403 samples showed signals above the LOD but below an OD_{450} of 0.35 (< than 2x LOD). 404 405 Similarly, out of the 770 Lyme Disease Biobank samples, 3 showed signals above the LOD with OD_{450} of 0.31, 0.49 and 0.59. The 8 samples with OD_{450} signals above the LOD using 406 407 the BdV38-based detection assay, were further confirmed to be within this same range when tested using the BdV234ACA assay (not shown), suggesting that these samples either carry 408 B. duncani at parasitemia levels below 0.5% or the BdV38 and BdV234 assays detect 409 antigens from other closely related pathogens. To gain further insights into the source of the 410 signals in these samples (N=9, one ARC30 sample also included), PCR-based amplification 411 analyses were conducted using the primer pairs listed in Table 2. Using primers designed to 412 be specific for B. duncani (specific to HSP-70, CelTos, and BdV38 genes), B. microti 413 (specific to BmITS and Bm GPI12 genes), B. divergens (specific to AMA-1 gene) and B. 414 MO1 (specific to the helicase gene), our PCR analyses showed that these samples do not 415 contain DNA from these species (Fig. S4-S5). To assess whether these samples contain DNA 416 from other *Babesia* species, we selected samples with the highest OD_{450} among these for 417 418 PCR analysis using a previously reported primer pair (39) that amplifies a 200 bp of the 18 S rRNA gene from multiple *Babesia* species (Fig. 6A). The nine samples included 1 from 419 ARC, 3 from Lyme Biobank and 5 from field mice. As shown in Fig. 6 B, six of the 9 420 421 samples tested positive by PCR. Sequencing of the 200 bp PCR product revealed sequences with 98 to 100% identity to 18S rRNA genes from Babesia species of Clade VI (B. divergens, 422 capreoli, B. odocoilei, and B. venatorum) (Table 3). To further evaluate these data, a new 423

424 primer set was designed to bind to conserved regions of the 18S rRNA genes of Babesia species and amplify a 736 bp. Using this primer set against all 9 samples, we found 5 (field 425 mice) samples to be positive by PCR. However, sequencing of the fragments failed to 426 427 identify a specific species at more than 90% sequence identify (Fig. S6 C-D). Together these data suggest that the 8 samples may contain new species of Babesia or closely related 428 organisms that the BdACAs can also detect. However, the exact identity of these new species 429 could not be determined due to limited amount of material available for large scale genomic 430 analyses. 431

432 **DISCUSSION**

Herein, we report the development of the first antigen capture assays, BdACAs, for the 433 detection of active B. duncani infection. The assays detect the presence of B. duncani-434 secreted antigens BdV38 (31 kDa) or BdV234 (27 kDa) in blood samples from infected 435 cultures or animals with high sensitivity and specificity. The BdACAs exhibit a remarkable 436 sensitivity in detecting these secreted *B*. *duncani* antigens from as little as a single drop of 437 blood, equivalent to 1.6×10^7 red blood cells, in both human and mouse samples. 438 Furthermore, the assay specifically distinguishes *B. duncani* infections when tested against 439 other human babesiosis-causing parasites (B. microti, B. divergens (Rouen87), Babesia MO1) 440 or related protozoan species (P. falciparum) that causes human malaria. These assays, 441 therefore, open up new possibilities for efficient and convenient diagnosis of B. duncani 442 infection, ensuring timely intervention and improved healthcare outcomes. The versatility of 443 this assay makes it useful in various setups, including point-of-care (POC) tests in clinics or 444 at home. Its potential applications include confirming acute *B. duncani* infection, screening 445 clinical samples, and ensuring the safety of blood supplies at blood donation centers, thereby 446 preventing transfusion-transmitted babesiosis. Additionally, it offers a valuable tool for 447 conducting epidemiological surveys to detect B. duncani infection in humans and reservoir 448 hosts. Given the urgent need for improved diagnostic tests to combat vector borne or 449 450 transfusion-transmitted babesiosis, as seen with other Babesia sp. in the USA, the development of this assay represents a significant stride toward achieving that goal (40, 41) 451 and the first report of an ELISA based antigen capture assay for B. duncani. 452

The current strategies employed for the detection of subclinical infections of intraerythrocytic parasites suffer from notable limitations. Microscopy, although widely used, exhibits low sensitivity and specificity, making it challenging to differentiate between various species of *Babesia* and other apicomplexan parasites, such as *Plasmodium*. Serological tests

457 such as immunofluorescence assays (IFA) lack reliability in distinguishing between acute and 458 chronic infections. On the other hand, PCR based assays that show high sensitivity to detect 459 parasite DNA can detect the DNA even after the infection has been cleared, as observed in 460 the case of *B. microti* (22). An ineffective diagnostic tool also hampers the proper 461 understanding of the epidemiological distribution of the parasite in its reservoir hosts.

One key advantage leveraged in our approach is the use of an in culture- in mouse (ICIM) 462 463 model system of B. duncani (42) infection, which allowed us to systematically examine different aspects of our assay, including optimizing the assay using various sample types such 464 465 as hemolysate, supernatant, whole blood, plasma, and serum. Additionally, the recent comprehensive genome analysis of B. duncani by Singh et. al. (29) shed light on the 466 abundance and nature of proteins, epigenome, and transcriptome analysis identified classes of 467 candidate virulence factors, antigens for diagnosis of active infection, and several attractive 468 drug targets. Studies in *B. microti* have shown that secreted proteins are excellent biomarkers 469 for the detection of active parasite infection (43, 44). These findings led to the development 470 471 of antigen capture assays (ACAs) for the detection of the secreted antigen BmGPI12 (22, 23).

Here, we have used an integrated approach consisting of genomic, transcriptomic, and 472 proteomic analyses to identify secreted proteins of *B. duncani*, which could be suitable as 473 biomarkers of active infection from different fractions (S, H, and P) (Table 1). Among the 474 pool of exported proteins, BdV234 and BdV38 were specifically chosen due to their 475 476 substantial peptide abundance and notably elevated expression levels (**Table 1**). We reasoned that those proteins with higher abundance and containing signal sequences were 477 predominantly destined for the extracellular space, where they could play a crucial role in 478 479 eliciting cell signaling and facilitating communication between host and parasite to promote infection propagation. To our surprise, our initial attempts to detect BdV234 and BdV38 480 directly from the plasma or serum of B. duncani-infected mice were unsuccessful. However, 481

by employing ultracentrifugation and the Exo-Quick approach, we were able to purify 482 extracellular vesicles (EVs) that contained these parasite proteins. The EVs containing these 483 B. duncani proteins may play a crucial role in the trafficking and delivery of these proteins, 484 allowing them to be expressed on the outer membrane of infected RBCs similar to that 485 reported for B. microti (30, 38). Our IFA results, from in vitro B. duncani-infected parasites, 486 further support the cellular distribution of these proteins. Further investigation is warranted to 487 488 explore the precise mechanism by which these proteins are sorted and packaged into EVs, as well as their specific role in mediating their transport to the surface of infected RBCs. 489 490 Understanding the molecular processes involved in this vesicular transport machinery will contribute to our overall comprehension of B. duncani pathogenesis and host-parasite 491 interactions. 492

This study assessed the field suitability of Bd38ACA by screening a diverse array of human 493 and mouse whole blood samples. The assay exhibited minimal cross-reactivity with both 494 human and field-derived white-footed mouse samples. However, a subset (0.4%) of samples 495 showed low reactivity with Bd38ACA, at levels significantly lower in comparison to the 496 positive control samples. Subsequent PCR analysis confirmed the absence of B. duncani 497 parasites in these samples but the exact organisms, likely a species closely related to B. 498 duncani, that cause the cross-reactivity detected in the BdACA assays remain to be further 499 characterized. 500

In conclusion, our findings demonstrate that BdACA is a reliable diagnostic assay for the detection of active *B. duncani* infection. It is suitable for large-scale screening of the blood supply and further optimization of the assay is warranted to test uninfected and infected human blood samples and compare with the current method (NAT assays) for blood screening. The development of such a diagnostic tool is a significant step forward in the fight

- 506 against *B. duncani* and can significantly improve the accuracy and efficiency of diagnosis,
- 507 treatment, and surveillance of this emerging tick-borne disease.

509 Figure legends:

Figure 1. Identification and detection of B. duncani secreted antigens. (A) Schematic 510 presentation for qualitative analysis of *B. duncani* secretome by nano-trap-based proteomics 511 approach (NTPA) utilizing ultracentrifugation and a tandem mass spectrometry analysis 512 (MS/MS) to identify Babesia duncani secreted proteins. (B) Immuno detection of secreted 513 BdV234 and BdV38 antigens from *B. duncani* infected human in vitro and mouse (ihRBCs, 514 imRBCs) culture supernatant (S), plasma (Pl), hemolysate (H) and parasite pellet (P) and 515 uninfected RBC (uhRBC, umRBC) with their corresponding protein size. (C) Western blot 516 analysis to detect BdV234 and BdV38 secreted antigens from extracellular vesicular fractions 517 obtained by ultracentrifugation approach using *B. duncani*-infected human and mouse RBCs. 518 After ultracentrifugation, the soluble fraction Us and the pellet fraction Up were collected 519 from the culture supernatant/plasma, and UHs and UHp fractions were obtained from the 520 hemolysate. Our data indicated that these proteins containing extracellular vesicles 521 accumulate in the pellet fraction Up/UHp from in vitro as well as from in vivo 522 supernatant/plasma or hemolysate. These measurements were conducted under both infected 523 (I) and uninfected (U) conditions. (D) Detection of BdV234 and BdV38 proteins from 524 extracellular vesicle supernatant (Es), and vesicle-rich pellet (Ev) fractions from both B. 525 duncani infected and uninfected in vitro culture supernatant and mouse plasma. Similar, 526 527 detection of protein from extracellular vesicles (EHs) and pellet (EHv) fractions of both human and mouse hemolysate samples. 528

529

Figure 2. Immunofluorescence assay for the detection of subcellular localization of *B*. *duncani* secreted proteins. Immunofluorescence staining of BdV234 and BdV38 proteins
using rabbit polyclonal anti-BdV234 and BdV38 antibodies. Samples were subsequently,

stained with an anti-rabbit secondary antibody conjugated with Alexa Fluor (AF)-488 533 (Green) in B. duncani - infected human RBCs. Anti-Band-III monoclonal antibody (Red) was 534 used to label the human erythrocyte plasma membrane, and DAPI (Blue) was used to stain 535 the parasite nucleus (DNA). The green fluorophore reveals both the localization and 536 distribution of the parasite-secreted proteins within or outside the host red blood cell. Immune 537 Sera: rabbit sera collected after injection of recombinant BdV234 and BdV38 recombinant 538 539 proteins, and preimmune sera: same rabbit sera collected before injection of recombinant proteins. Differential Interference Contrast (DIC). Scale bars, 5µm. 540

541

Figure 3. Development and detection of active *B. duncani* infection by BdACA. (A) 542 Schematic representation of the ELISA-based B. duncani antigen capture assay (BdACA). B. 543 544 duncani secreted antigens (recombinant proteins) BdV234 and BdV38 were used as specific biomarkers for the detection of parasite infection. Respective antigen-specific polyclonal 545 546 antibodies (ASPA) were used as both capture and biotinylated-detection antibodies to detect the B. duncani secreted antigens (BdV234 and BdV38). (B) A standard curve with 547 recombinant BdV234 and BdV38 proteins was tested in two-fold serial dilutions. (C-F) A 548 dose-response curve showing the absorbance at 450 nm (y-axis) plotted against two-fold 549 serial diluted supernatant (C) and hemolysate (D) obtained from *in vitro* cultures of B. 550 551 *duncani* infected human erythrocytes and from *B. duncani* infected mouse plasma/serum (E) and hemolysate (F) along with uninfected hRBC/mRBC as controls (black and grey). The 552 specific polyclonal antibodies were used to detect BdV234 (pink, triangle) and BdV38 (blue, 553 circle) antigens. The error bars represent the standard deviation (SD), calculated using 554 GraphPad Prism 9.3 software. All samples were analyzed in two independent experiments in 555 triplicates. 556

557

Figure 4. BdACA shows high sensitivity to detect *B. duncani*-infected human and mouse 558 red blood cells. (A) Scatter plot illustrates the corelation between cycle threshold values (Cq) 559 and the number of *B. duncani*-infected red blood cells (iRBCs). Cq values were obtained 560 through q-PCR analysis using Bd ITS (18S rRNA) primers on isolated genomic DNA from 561 562 indicated parasites. The graph ploted using Cq values on the Y-axis against the number of iRBCs on the X-axis, from an in vitro B. duncani culture. Horizontal dotted line represents 563 the cut-off threshold, with numerical values on the x-axis depicting the quantity of infected 564 RBCs, where 'x 10³' denotes a scale of 1000 for RBC count. (B-C) Detection of BdV38 (B) 565 and BdV234 (C) secreted antigens from B. duncani-infected human RBCs from in vitro 566 culture samples with different dilutions of parasites as shown in the bar graph, and the % 567 parasitemia was counted by Giemsa stain (black scatter plot). (D-F) Babesia duncani in vitro 568 culture, diluted to 0.5% parasitemia (5% hematocrite), was incubated at 37°C. Samples were 569 collected over time, beginning zero hour post-inoculationt to 48 hours. Genomic DNA was 570 isolated from these samples and quantified using qPCR targeting the 18S rRNA gene (**D**). 571 Similarly, hemolysate fractions were prepared to detect the BdV38 (E) and BdV234 (F) 572 573 antigens from these samples. (G-I) For sensitivity analysis from in vivo samples, C3H/HeJ mice were inoculated with 10⁶ parasites and monitored. Parasites were collected at various 574 575 time points (0-7 dpi) post-infection and subjected for quantification of the 18S rRNA gene by qPCR (G). BdACAs detection of BdV38 (H) and BdV234 (I) antigens from B. duncani 576 infected mouse erythrocytes after post-inoculation. Blood from uninfected mice was utsed as 577 control. The dashed lines show the limit of blank (LOB, gray) and the limit of detection 578 (LOD, black), respectively. NTC: non template control, UC: uninfected control, iRBC: 579 infected red blood cells, uRBC: uninfected red blood cells. 580

581

Figure 5. Detection of BdV38 antigen after Tafenoquine treatment of B. duncani 582 cultures. (A and D) Percent parasitemia over time from B. duncani in vitro culture (A) or 583 mouse infected with B. duncani (D) in vehicale (PEG-400) untreated (UT) or tafenoquine 584 treated (1x IC₅₀ and 2x IC₅₀ TQ samples over time. (**B and E**) Bd38ACA detection of BdV38 585 antigen in *B. duncani in vitro* culture hemolysate (**B**) and *B. duncani* 10^6 infected mouse 586 hemolysate (E) in untreated or tafenoquine treated samples. (C and F) genomic DNA 587 588 isolated from parasites from in vitro (C) or mice (F) at different time points pre and post tafenoquine treatment were subjected to B. duncani 18S rRNA quantitative PCR. Graphs 589

590 denote the Cq values over time.

Figure 6. In vitro and In vivo specificity of BdACAs for Babesia antigens. Bd38ACA (A-591 **B**) or Bd234ACA (**C-D**) were performed on uninfected (Bd-U) or *B. duncani*-infected (Bd-I) 592 (24% parasitemia) C3H/HeJ mouse hemolysate and uninfected (Bm-U) or B. microti-infected 593 (Bm-I) (70% parasitemia) CB17 SCID mouse hemolysate (A and C). In vitro culture 594 hemolysate from uninfected (RBC) or B. duncani (Bd) (10 % parasitemia), B. divergens 595 Rouen87 (B.div) (10 % parasitemia), B. MO1 (10 % parasitemia) (MO1), and P. falciparum 596 (Pf3D7) (10% parasitemia) infected samples (B and D). Bd- Babesia duncani, Bm- Babesia 597 microti, B.div- Babesia divergens rouen87, Pf3D7- Plasmodium falciparum 3D7, I-infected, 598 U- uninfected, cF12-complete DMEM-F12, and cRPMI-complete RPMI media. The gray 599 600 dashed lines show the limit of blank (LOB,) and black deshed line show the limit of detection (LOD) ($OD_{450}=0.3$). respectively. Error bars showing the standard deviation (SD) 601 which were calculated by GraphPad Prism 9.3. 602

603

Figure 7. Bd38ACA screening of ARC, LDB human patient samples, and untested fieldderived white-footed mouse samples. (A) Screening of known positive and negative

606 Babesia patient samples, Lyme positive and negative samples, and unknown infection from field-derived white-footed mouse samples with Bd38ACA. One hundred B. microti 607 transcription-mediated amplification (TMA)-positive human patient samples (blue open 608 609 upward triangle), 100 TMA-negative human patient samples (blue closed inverted triangle) from American Red Cross (ARC), 478 Lyme disease positive (orange open circle), and 292 610 control samples (orange closed circle) from Lyme Disease Biobank (LDB) samples (770 611 samples) and 761 unknown field mice samples (purple open diamond) were tested. Each 612 sample was used in triplicates. (B) Two fold serially dilutaed B. duncani infected human 613 614 RBC hemolysate (ihRBC; gray bar graph) were used as positive controls to compare the samples OD₄₅₀ in corelation with % parasitemia. Black and red dash lines show the limit of 615 blank (LOB) and limit of detection (LOD) respectively. Error bars showing the standard 616 617 deviation (SD) were calculated using GraphPad Prism 9.3 software. (*) showing OD450 of patient samples that were slightly positive for Bd38ACA. 618

620 Author contributions

MC, PV, DD, LZ, JC, and AP: Investigation, methodology, formal analysis, visualization, writing original draft, review, and editing. SW: Sample collection and analysis. CB: Conceptualization, supervision, funding acquisition, project administration, writing original draft, review, and editing. All authors have read and agreed to the published version of the manuscript. All authors contributed to the article and approved the submitted version.

626

627 Funding

The research described herein was supported by the Global Lyme Alliance Foundation. CBM
research is also supported by NIH grants AI138139, AI123321, AI152220 and AI153100,
and AI136118, the Steven and Alexandra Cohen Foundation (Lyme 62 2020), and The
Blavatnik Family Foundation.

632

633 Acknowledgments

We thank the American Red Cross and the Lyme Disease Biobank for providing the bloodsamples used in this study.

636 **References**

- Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P. 2008. Global
 trends in emerging infectious diseases. Nature 451:990-3.
- Eisen RJ, Eisen L, Beard CB. 2016. County-Scale Distribution of Ixodes scapularis and
 Ixodes pacificus (Acari: Ixodidae) in the Continental United States. J Med Entomol 53:349-
- 641 86.
- 642 3. Eisen RJ, Kugeler KJ, Eisen L, Beard CB, Paddock CD. 2017. Tick-Borne Zoonoses in the
 643 United States: Persistent and Emerging Threats to Human Health. Ilar j 58:319-335.
- 4. Rosenberg R, Lindsey NP, Fischer M, Gregory CJ, Hinckley AF, Mead PS, Paz-Bailey G,
 Waterman SH, Drexler NA, Kersh GJ, Hooks H, Partridge SK, Visser SN, Beard CB,
 Petersen LR. 2018. Vital Signs: Trends in Reported Vectorborne Disease Cases United
- 647 States and Territories, 2004-2016. MMWR Morb Mortal Wkly Rep 67:496-501.
- 648 5. Renard I, Ben Mamoun C. 2021. Treatment of Human Babesiosis: Then and Now. Pathogens
 649 10.
- 650 6. Swanson M PA, Williamson J, Montgomery S. 2023. Trends in Reported Babesiosis Cases —
 651 United States, 2011–2019.
- Puri A, Bajpai S, Meredith S, Aravind L, Krause PJ, Kumar S. 2021. Babesia microti:
 Pathogen Genomics, Genetic Variability, Immunodominant Antigens, and Pathogenesis.
 Front Microbiol 12:697669.
- 8. Vannier E, Gewurz BE, Krause PJ. 2008. Human babesiosis. Infect Dis Clin North Am
 22:469-88, viii-ix.
- 9. Vannier EG, Diuk-Wasser MA, Ben Mamoun C, Krause PJ. 2015. Babesiosis. Infect Dis Clin
 North Am 29:357-70.
- 659 10. Gray EB HB. 2019. Babesiosis Surveillance United States, 2011–2015. MMWR Surveill
 660 Summ 68:1–11.
- 661 11. O'Connor KE, Kjemtrup AM, Conrad PA, Swei A. 2018. An Improved PCR Protocol For
 662 Detection of Babesia duncanI In Wildlife and Vector Samples. J Parasitol 104:429-432.

- Conrad PA, Kjemtrup AM, Carreno RA, Thomford J, Wainwright K, Eberhard M, Quick R,
 Telford SR, 3rd, Herwaldt BL. 2006. Description of Babesia duncani n.sp. (Apicomplexa:
 Babesiidae) from humans and its differentiation from other piroplasms. Int J Parasitol 36:77989.
- Swei A, O'Connor KE, Couper LI, Thekkiniath J, Conrad PA, Padgett KA, Burns J,
 Yoshimizu MH, Gonzales B, Munk B, Shirkey N, Konde L, Ben Mamoun C, Lane RS,
 Kjemtrup A. 2019. Evidence for transmission of the zoonotic apicomplexan parasite Babesia
 duncani by the tick Dermacentor albipictus. Int J Parasitol 49:95-103.
- 4. Quick RE, Herwaldt BL, Thomford JW, Garnett ME, Eberhard ML, Wilson M, Spach DH,
 Dickerson JW, Telford SR, 3rd, Steingart KR, Pollock R, Persing DH, Kobayashi JM,
 Juranek DD, Conrad PA. 1993. Babesiosis in Washington State: a new species of Babesia?
 Ann Intern Med 119:284-90.
- Herwaldt BL, Kjemtrup AM, Conrad PA, Barnes RC, Wilson M, McCarthy MG, Sayers MH,
 Eberhard ML. 1997. Transfusion-transmitted babesiosis in Washington State: first reported
 case caused by a WA1-type parasite. J Infect Dis 175:1259-62.
- Bloch EM, Herwaldt BL, Leiby DA, Shaieb A, Herron RM, Chervenak M, Reed W, Hunter
 R, Ryals R, Hagar W, Xayavong MV, Slemenda SB, Pieniazek NJ, Wilkins PP, Kjemtrup
 AM. 2012. The third described case of transfusion-transmitted Babesia duncani. Transfusion
- **681 52:1517-22.**
- Kjemtrup AM, Conrad PA. 2000. Human babesiosis: an emerging tick-borne disease. Int J
 Parasitol 30:1323-37.
- Fritz CL, Kjemtrup AM, Conrad PA, Flores GR, Campbell GL, Schriefer ME, Gallo D, Vugia
 DJ. 1997. Seroepidemiology of emerging tickborne infectious diseases in a Northern
 California community. J Infect Dis 175:1432-9.
- Persing DH, Herwaldt BL, Glaser C, Lane RS, Thomford JW, Mathiesen D, Krause PJ,
 Phillip DF, Conrad PA. 1995. Infection with a babesia-like organism in northern California. N
 Engl J Med 332:298-303.

- 690 20. Scott JD, Scott CM. 2018. Human Babesiosis Caused by Babesia duncani Has Widespread
- 691Distribution across Canada. Healthcare (Basel) 6.
- Healy GR, Speilman A, Gleason N. 1976. Human babesiosis: reservoir in infection on
 Nantucket Island. Science 192:479-80.
- 694 22. Thekkiniath J, Mootien S, Lawres L, Perrin BA, Gewirtz M, Krause PJ, Williams S, Doggett
- JS, Ledizet M, Ben Mamoun C. 2018. BmGPAC, an Antigen Capture Assay for Detection of
 Active Babesia microti Infection. J Clin Microbiol 56.
- 697 23. Gagnon J, Timalsina S, Choi JY, Chand M, Singh P, Lamba P, Gaur G, Pal AC, Mootien S,
- 698 Marcos LA, Ben Mamoun C, Ledizet M. 2022. Specific and Sensitive Diagnosis of Babesia
- 699 microti Active Infection Using Monoclonal Antibodies to the Immunodominant Antigen700 BmGPI12. J Clin Microbiol 60:e0092522.
- Caminade C, McIntyre KM, Jones AE. 2019. Impact of recent and future climate change on
 vector-borne diseases. Ann N Y Acad Sci 1436:157-173.
- 703 25. Gilbert L. 2021. The Impacts of Climate Change on Ticks and Tick-Borne Disease Risk.
 704 Annu Rev Entomol 66:373-388.
- 26. Abraham A, Brasov I, Thekkiniath J, Kilian N, Lawres L, Gao R, DeBus K, He L, Yu X, Zhu
- G, Graham MM, Liu X, Molestina R, Ben Mamoun C. 2018. Establishment of a continuous in
 vitro culture of Babesia duncani in human erythrocytes reveals unusually high tolerance to
 recommended therapies. J Biol Chem 293:19974-19981.
- 709 27. Kumari V, Pal AC, Singh P, Mamoun CB. 2022. Babesia duncani in Culture and in Mouse
 710 (ICIM) Model for the Advancement of Babesia Biology, Pathogenesis, and Therapy. Bio
 711 Protoc 12.
- 712 28. Singh P, Pal AC, Mamoun CB. 2022. An Alternative Culture Medium for Continuous In
 713 Vitro Propagation of the Human Pathogen Babesia duncani in Human Erythrocytes.
 714 Pathogens 11.
- Singh P, Lonardi S, Liang Q, Vydyam P, Khabirova E, Fang T, Gihaz S, Thekkiniath J,
 Munshi M, Abel S, Ciampossin L, Batugedara G, Gupta M, Lu XM, Lenz T, Chakravarty S,
 Cornillot E, Hu Y, Ma W, Gonzalez LM, Sánchez S, Estrada K, Sánchez-Flores A, Montero

718 E, Harb OS, Le Roch KG, Mamoun CB. 2023. Babesia duncani multi-omics identifies virulence factors and drug targets. Nat Microbiol 8:845-859. 719 30. Thekkiniath J, Kilian N, Lawres L, Gewirtz MA, Graham MM, Liu X, Ledizet M, Ben 720 Mamoun C. 2019. Evidence for vesicle-mediated antigen export by the human pathogen 721 722 Babesia microti. Life Sci Alliance 2. 723 31. Baranyai T, Herczeg K, Onódi Z, Voszka I, Módos K, Marton N, Nagy G, Mäger I, Wood MJ, El Andaloussi S, Pálinkás Z, Kumar V, Nagy P, Kittel Á, Buzás EI, Ferdinandy P, Giricz 724 725 Z. 2015. Isolation of Exosomes from Blood Plasma: Qualitative and Quantitative Comparison of Ultracentrifugation and Size Exclusion Chromatography Methods. PLoS One 726 10:e0145686. 727 728 32. Chand M, Choi JY, Pal AC, Singh P, Kumari V, Thekkiniath J, Gagnon J, Timalsina S, Gaur 729 G, Williams S, Ledizet M, Mamoun CB. 2022. Epitope profiling of monoclonal antibodies to 730 the immunodominant antigen BmGPI12 of the human pathogen Babesia microti. Front Cell Infect Microbiol 12:1039197. 731 732 33. Wang Y, Zhang S, Wang J, Rashid M, Wang X, Liu X, Yin H, Guan G. 2022. Nested qPCR 733 assay to detect Babesia duncani infection in hamsters and humans. Parasitol Res 121:3603-734 3610. Wang G, Wormser GP, Zhuge J, Villafuerte P, Ip D, Zeren C, Fallon JT. 2015. Utilization of 735 34. a real-time PCR assay for diagnosis of Babesia microti infection in clinical practice. Ticks 736 Tick Borne Dis 6:376-82. 737 Horn EJ, Dempsey G, Schotthoefer AM, Prisco UL, McArdle M, Gervasi SS, Golightly M, 738 35. 739 De Luca C, Evans M, Pritt BS, Theel ES, Iyer R, Liveris D, Wang G, Goldstein D, Schwartz I. 2020. The Lyme Disease Biobank: Characterization of 550 Patient and Control Samples 740 from the East Coast and Upper Midwest of the United States. J Clin Microbiol 58. 741 Tamburro D, Fredolini C, Espina V, Douglas TA, Ranganathan A, Ilag L, Zhou W, Russo P, 742 36. Espina BH, Muto G, Petricoin EF, 3rd, Liotta LA, Luchini A. 2011. Multifunctional core-743 shell nanoparticles: discovery of previously invisible biomarkers. J Am Chem Soc 744 745 133:19178-88.

- 746 37. Magni R, Luchini A, Liotta L, Molestina RE. 2019. Analysis of the Babesia microti proteome
 747 in infected red blood cells by a combination of nanotechnology and mass spectrometry. Int J
 748 Parasitol 49:139-144.
- 749 38. Beri D, Rodriguez M, Singh M, Liu Y, Rasquinha G, An X, Yazdanbakhsh K, Lobo CA.
- 750 2022. Identification and characterization of extracellular vesicles from red cells infected with
- 751Babesia divergens and Babesia microti. Front Cell Infect Microbiol 12:962944.
- 752 39. Qurollo BA, Archer NR, Schreeg ME, Marr HS, Birkenheuer AJ, Haney KN, Thomas BS,
- Breitschwerdt EB. 2017. Improved molecular detection of Babesia infections in animals using
 a novel quantitative real-time PCR diagnostic assay targeting mitochondrial DNA. Parasit
 Vectors 10:128.
- Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M. 2011.
 Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med 155:509-19.
- Fang DC, McCullough J. 2016. Transfusion-Transmitted Babesia microti. Transfus Med Rev
 30:132-8.
- Pal AC, Renard I, Singh P, Vydyam P, Chiu JE, Pou S, Winter RW, Dodean R, Frueh L,
 Nilsen AC, Riscoe MK, Doggett JS, Ben Mamoun C. 2022. Babesia duncani as a Model
 Organism to Study the Development, Virulence, and Drug Susceptibility of Intraerythrocytic
 Parasites In Vitro and In Vivo. J Infect Dis 226:1267-1275.
- Filton CM, Rodriguez M, Ben Mamoun C, Lobo CA, Wright GJ. 2019. A library of
 recombinant Babesia microti cell surface and secreted proteins for diagnostics discovery and
 reverse vaccinology. Int J Parasitol 49:115-125.
- 44. Luo Y, Jia H, Terkawi MA, Goo YK, Kawano S, Ooka H, Li Y, Yu L, Cao S, Yamagishi J,
 Fujisaki K, Nishikawa Y, Saito-Ito A, Igarashi I, Xuan X. 2011. Identification and
 characterization of a novel secreted antigen 1 of Babesia microti and evaluation of its
 potential use in enzyme-linked immunosorbent assay and immunochromatographic test.
 Parasitol Int 60:119-25.

Α





С

	<i>In vitro</i> Culture Supernatant			ire nt	<i>In vitro</i> Culture hemolysate		Mouse Plasma			Mouse hemolysate				
			U			U	U U		<u> </u>		U			
	Us	Up	Us	Up	UHs UHp	UHs UHp	Us	Up	Us	Up	UHs	UHp	UHs UHp	kDa
BdV234 ➡		-		1	-			-				-	1	- 27
BdV38 ➡			•		1					1		-	the second	- 31











Α

2.0-2.0-BdV38 detection (in vitro) BdV38 detection (in vivo) 1.5 1.5 OD at 450nm OD at 450nm 1.0 1.0 0.5 0.5 LOD LOB 0.0 0.0 RBC **I** Bd Bd-U . Bd-l B.div MO1 Pf3D7 Bm-U Bm-I С D 2.5 2.0 BdV234 detection (*in vivo*) OD at 450nm BdV234 detection (in vitro) 2.0 1.5 OD at 450nm 1.5-1.0 1.0 0.5 0.5 LOD LOB ĽOD LOB 0.0 0.0 B.div MO1 Pf3D7 RBC Bd-U Bd-I Bm-U Bm-I Bd

В

Α

В



Accession ID	ccession ID Description		Number of Peptides	Number of amino acids	MW [kDa]	RNAseq (TPM)#
BdWA1_000818-T1	Actin, putative	High	5	376	41.9	6836.72
BdWA1_000589-T1	phosphatidylinositol-4-phosphate 5- kinase, putative	High	4	1074	121.8	278.21
BdWA1_002814-T1	Thioredoxin domain Thioredoxin, conserved site Thioredoxin-like superfamily	High	4	490	54.4	1398.21
BdWA1_000266-T1	hypothetical protein, conserved	High	3	498	57.4	21.68
BdWA1_001049-T1	Hsp20/alpha-crystallin family, putative	High	3	177	20.1	8294.36
BdWA1_002869-T1	hypothetical protein, conserved	High	3	215	24.6	778.09
BdWA1_003373-T1	hypothetical protein	High	1	127	12.5	8199.71
BdWA1_001726-T1	RAP domain/Core histone H2A/H2B/H3/H4, putative	High	3	132	14.5	26809.25
BdWA1_002223-T1	BdV234 (GPI-anchored protein BdGPI8)	High	2	242	27.2	1655.60
BdWA1_001531-T1	hypothetical protein	High	3	375	41.4	4774.64
BdWA1_003044-T1	heat shock protein 70 precursor, putative	High	2	644	70.6	2621.88
BdWA1_001730-T1	BdV38 (putative EF-hand domain)	High	1	292	33	1426.92
BdWA1_001385-T1	40S ribosomal protein S3 protein, putative	High	1	224	25	1702.62
BdWA1_000947-T1	heat shock protein 90	High	2	713	82.3	4798.62
BdWA1_001677-T1	Sodium: dicarboxylate symporter family, putative	High	1	789	89.4	272.46
BdWA1_002995-T1	NAC domain-containing protein, putative	High	1	159	17.1	575.40
BdWA1_001746-T1	hypothetical protein, conserved	High	1	374	42.8	667.65
BdWA1_001707-T1	heat shock protein 70 precursor, putative	High	2	654	71.9	0.98
BdWA1_001359-T1	histone H3, putative	High	2	136	15.4	21963.75
BdWA1_002631-T1	Porin domain superfamily	High	1	298	32.9	572.95
BdWA1_000088-T1	hypothetical protein	High	1	601	68.4	17.86
BdWA1_001694-T1	Enolase, N-terminal domain / Enolase, C-terminal TIM barrel domain-containing protein, putative	Medium	1	442	47.6	4.71
BdWA1_000240-T1	BdGPI17	Medium	1	618	69.8	1674.59
BdWA1_000444-T1	myosin A	Medium	1	827	92.4	7.04
BdWA1_002345-T1	cytochrome c oxidase subunit 2, putative	Medium	1	168	19.1	353.85
BdWA1_002720-T1	transporter, putative	Medium	1	445	50.6	1769.55
BdWA1_000077-T1	Armadillo-type fold Armadillo-like helical Armadillo repeat-containing protein 6 Armadillo	Medium	1	2574	283.2	947.97

Table 1. List of proteins identified in the supernatant of *B. duncani*-infected human erythrocytes using nano trap technology.

* FDR (False discovery rate) # Singh et al., Nature Microbiology 2023

S. No.	Primer set	Forward primer	Reverse primer
1	BdHSP70	TGAATGCGGGAGCTGGATGTAAG	TCAACACAGTCATGACACCACCAG
2	BdCelToS	ATGAAGTTCTTTTCCGTTTTATTCC	AAAGTCGTCGTCGTCTAGTG
3	BdV38-1	GTGGAGCTGGCAAAGTTCTC	TGGCATGAAAGGCCGCC
4	BmITS	TCCCATTTGGGTTACGCTGG	CGTGCAGACAAACCCGCCTT
5	BmGPI12	CATAATCACTGCTTTCGCAG	CATCCACTTCAGCACCAG
6	B.div AMA-1	CCAGAGGAAGGCAACAGTCCTC	CTGCATGGGCGTGAAGAGG
7	B. MO1 Helicase	TCGGAAGAATTTCATCAAAC	AGTCGAAATGGACAAGGTC
8	Babesia 18S rRNA (736bp)	GAGGGCAAGTCTGGTGCCAGC	CCAGACAAATCACTCCACCAAC
9	B. common 18S rRNA (200bp)	GAGGGCAAGTCTGGTGCCAGC	CCAGACAAATCACTCCACCAAC

Table 2. List of primer sequences for *Babesia* and species -specific PCRs.

Table 3. List of PCR positive samples with identity scores to 18S rRNA of *Babesia* species genes from of Clade VI.

Sample ID	Gene description	Species	Percent Identity	Accession No.
LDB85		Babesia odocoilei isolate JC34	99.21	<u>KY805843.1</u>
	Small subunit ribosomal RNA	Babesia odocoilei isolate JC09	99.21	<u>KY805842.1</u>
	gene (18S rRNA)	Babesia capreoli isolate GM19	99.21	<u>KY805834.1</u>
		Babesia sp. venatorum isolate RD8	99.21	<u>MG344777.1</u>
LDB139		Babesia odocoilei isolate JC34	98.52	<u>KY805843.1</u>
	Small subunit ribosomal RNA	Babesia odocoilei isolate JC09	98.52	<u>KY805842.1</u>
	gene (18S rRNA)	Babesia capreoli isolate GM19	98.52	<u>KY805834.1</u>
		Babesia sp. venatorum isolate RD8	98.52	<u>MG344777.1</u>
FM1		Babesia odocoilei isolate JC34	98.04	<u>KY805843.1</u>
	Small subunit ribosomal RNA gene (18S rRNA)	Babesia odocoilei isolate JC09	98.04	<u>KY805842.1</u>
		Babesia odocoilei isolate YB73	98.04	<u>KY805835.1</u>
		Babesia sp. venatorum isolate R30	98.04	<u>MG062781.1</u>
FM7		Babesia odocoilei isolate JC34	100.00	<u>KY805843.1</u>
	Small subunit ribosomal RNA	Babesia odocoilei isolate JC09	100.00	<u>KY805842.1</u>
	gene (18S rRNA)	Babesia capreoli isolate GM19 s	100.00	<u>KY805834.1</u>
		Babesia sp. venatorum isolate RD8	100.00	<u>MG344777.1</u>
FM8		Babesia odocoilei isolate JC34	100.00	<u>KY805843.1</u>
	Small subunit ribosomal RNA	Babesia odocoilei isolate JC09	100.00	<u>KY805842.1</u>
	gene (18S rRNA)	Babesia capreoli isolate GM19	100.00	<u>KY805834.1</u>
		Babesia sp. venatorum isolate R30	100.00	<u>MG062781.1</u>
FM15		Babesia odocoilei isolate JC34	98.33	<u>KY805843.1</u>
	Small subunit ribosomal RNA	Babesia odocoilei isolate JC09	98.33	<u>KY805842.1</u>
	gene (185 rKNA)	Babesia capreoli isolate GM19 s	98.33	<u>KY805834.1</u>
		Babesia sp. venatorum isolate RD8	98.33	<u>MG344777.1</u>